Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination October 26, 2022
First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients October 26, 2022
Development of CYAD-101, Allogeneic TIM-based, NKG2D CAR T Candidate for Metastatic Colorectal Cancer (mCRC), to be discontinued October 19, 2022
First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Ph 1/2/3 Clinical Study for Natrunix™ Therapy for Colorectal Cancer October 19, 2022
First Patient Enrolled in Part C of Ph 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer October 19, 2022
Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option Announced October 19, 2022
Part 3 of the CORIST Ph 2 trial of SCO-101 as a combination treatment in patients with metastatic colorectal cancer (mCRC) initiated October 12, 2022
Randomized Ph 2 trial of onvansertib + SoC FOLFIRI/bevacizumab announced in 2L RAS-mutated mCRC September 28, 2022
TUKYSA® (tucatinib) + Trastuzumab combo Granted Priority Review by FDA for Previously Treated HER2+ve Metastatic CRC September 28, 2022
Lumakras® (Sotorasib) + Vectibix® (Panitumumab) Shows Confirmed 30% ORR In Patients With KRAS G12C-Mutated mCRC September 13, 2022
Imfinzi + chemo further improved OS benefit in advanced biliary tract cancer in the TOPAZ-1 Ph 3 trial, reducing the risk of death by 24% in additional follow-up September 13, 2022
Adagrasib +/- cetuximab demonstrates promising clinical efficacy and favorable tolerability in heavily pretreated CRC patients with KRASG12C mutation September 13, 2022
Camrelizumab + Rivoceranib (Apatinib) Significantly Prolonged OS & PFS vs Sorafenib in Patients with uHCC in a Multinational Ph 3 Trial September 13, 2022
Results From Ph 3 LEAP-002 Trial of KEYTRUDA® + LENVIMA® Versus LENVIMA Monotherapy in Patients With uHCC presented September 13, 2022
Tislelizumab demonstrated efficacy and tolerability in 1L advanced liver cancer in Ph 3 RATIONALE 301 trial September 13, 2022
Trifluridine/tipiracil + bevacizumab showed a statistically significant OS improvement vs trifluridine/tipiracil alone in Ph 3 trial in mCRC patients September 13, 2022
Imfinzi plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced biliary tract cancer September 13, 2022
Imfinzi plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced BTC September 7, 2022
EMA Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer June 14, 2022
